Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J
You may also be interested in...
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.